---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-009397"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2024-01-31T23:59:59+00:00"
generated_at: "2026-06-06T14:31:56.722129+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# ARCA biopharma grants options to 7 non-employee directors; stockholders re-elect two directors at annual meeting

## Summary
- Board granted options to purchase 6,000 shares each to 7 non-employee directors at $1.64 per share, vesting monthly over 12 months.
- Stockholders re-elected Michael Bristow (6,952,545 for) and Robert Conway (6,758,409 for) as directors for three-year terms.
- Ratified KPMG LLP as independent auditor for FY2023 with 10,286,650 for, 263,929 against, 68,141 abstain.
- Advisory say-on-pay resolution approved: 6,548,473 for, 1,472,454 against, 19,941 abstain.

## SEC filing metadata
- accession: 0000950170-24-009397
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2024-01-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000095017024009397/0000950170-24-009397-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000095017024009397/abio-20240130.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-009397
- JSON: https://secwatch.observer/filing/0000950170-24-009397.json
- Plain text: https://secwatch.observer/filing/0000950170-24-009397.txt

## Key facts
- Shareholder Votes
  Oruka Therapeutics, Inc. shareholders approved Election of Directors at the 2024-01-30 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2024-01-30
  source text: Nominee For Withheld Broker Non-Votes Dr. Michael R. Bristow 6,952,545 1,088,323 2,577,852 Mr. Robert E. Conway 6,758,409 1,282,459 2,577,852
  evidence_url: https://www.sec.gov/Archives/edgar/data/907654/000095017024009397/0000950170-24-009397-index.htm
- Shareholder Votes
  Oruka Therapeutics, Inc. shareholders approved Advisory vote on the compensation of the Company’s named executive officers at the 2024-01-30 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2024-01-30
  source text: For Against Abstentions Broker Non-Votes 6,548,473 1,472,454 19,941 2,577,852
  evidence_url: https://www.sec.gov/Archives/edgar/data/907654/000095017024009397/0000950170-24-009397-index.htm
- Shareholder Votes
  Oruka Therapeutics, Inc. shareholders approved Ratification of the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2024-01-30 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2024-01-30
  source text: For Against Abstentions Broker Non-Votes 10,286,650 263,929 68,141 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/907654/000095017024009397/0000950170-24-009397-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.